Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(22%)
Results Posted
125%(5 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
3
33%
Ph phase_3
4
44%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Recruiting2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 34 (50.0%)

Trials by Status

completed444%
unknown111%
recruiting222%
terminated222%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_3

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710
terminatedphase_2

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

NCT05634577
recruitingphase_2

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

NCT06831175
completedphase_3

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

NCT00304070
completed

The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

NCT05344027
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03583710Phase 3

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Recruiting
NCT05634577Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Terminated
NCT06831175Phase 2

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting
NCT00304070Phase 3

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Completed
NCT05344027

The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

Completed
NCT00777244Phase 3

Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

Unknown
NCT00094497Phase 3

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Completed
NCT02057237Phase 1

A Safety and Feasibility Study of Mitotane in Prostate Cancer

Completed
NCT00778817Phase 2

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9